The New Prostatefocus Genetic Screening Test Identifies Men at Increased Risk of Developing Prostate Cancer
Our new Prostatefocus cancer genetic screening test identifies men at increased risk of developing prostate cancer. Prostate cancer is the most common cancer in men with 50,000 people in the UK diagnosed with the disease each year. 1 in 8 men in the UK will develop...
New Allergyfocus Test from Oncologica identifies over 99% of common allergies
Our new Allergyfocus test helps sufferers discover what common global allergens their bodies react to. Across the world allergies are on the rise. It is estimated that 20% of children and 30% of adults develop allergies in their lifetime. People can be allergic to...
Oncologica new research on detection of brain cancer biomarkers by genomic sequencing to improve survival rates
Glioblastoma, the most aggressive form of brain cancer is commonly treated with surgery, radiation, and chemotherapy. However, a newly published study from the research team at Oncologica the world-leading genetic cancer testing laboratory based in Cambridge UK,...
COVID vaccination, PCR testing and variant sequencing: The key to safe cross-border travel
With many people ditching staycations for trips overseas, the risk of traveller related introduction of high-risk COVID19 variants into the UK is a major issue surrounding European and international holiday travel. The UK government day 2 and day 8 covid...
Oncologica® video follows COVID-19 PCR swab through genomic lab test
For international travellers, taking their PCR test swab is only the beginning of the Coronavirus PCR test journey. In a meeting with Robert Courts MP, Minister for Aviation, Maritime & Security, Oncologica® explained the genetic science and logistics applied...
UK Test and Sequence Strategy Aims to Block Emerging COVID-19 Strains
Genomic sequencing is yielding critical insights into how the SARS-CoV-2 virus mutates, which variants are the most infectious and how it travels from place to place. Yet sequencing is still rare in most countries, and more than a year since the virus made its...
Oncologica®’s Coronafocus COVID-19 Test and Sequence platform enables rapid identification of variants of concern
The emergence of Covid-19 variants are a potential threat to the successful global vaccination programmes. Like all viruses, SARS-CoV-2 evolves over time through the acquisition of random mutations in its genome which is an innate characteristic of viral...
Utilisation of semiconductor sequencing for the detection of predictive biomarkers in glioblastoma
Glioblastoma is the most aggressive form of brain cancer, with debilitating symptoms including seizures, memory loss, difficulties in language processing, muscle weakness and visual changes. The standard treatment for glioblastoma involves a combination of surgery,...
Oncologica® launches an integrated Test and Sequence platform to combine high capacity PCR testing with SARS-CoV-2 variant identification
The Covid-19 pandemic has had major impact on the social and economic activities of the United Kingdom and has resulted in many deaths. The two major initiatives to address the pandemic has been the establishment of high capacity Covid-19 testing coupled to track...
Immunotherapy: an anti-cancer treatment based on harnessing our own immune system to attack cancer cells
Immunotherapy, in which the body’s own immune system is harnessed to kill cancer cells in patients with advanced disease, is proving a powerful treatment in around 15% of cancer patients. Importantly this type of treatment can be used to treat a broad range of...